Secondary Clinical Trial
— LAL1913Official title:
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
Verified date | September 2021 |
Source | Gruppo Italiano Malattie EMatologiche dell'Adulto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will be conducted in different centres and will study adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). The study treatment will include a induction/consolidation therapy incorporating pegylated Asparaginase (Peg-ASP) and lineage-targeted high-dose methotrexate plus other antileukemic drugs, for the achievement of an early negative minimal residual disease (MRD) status. The MRD study supports a risk/MRD-oriented final consolidation phase.
Status | Completed |
Enrollment | 204 |
Est. completion date | December 7, 2020 |
Est. primary completion date | October 7, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Signed written informed consent according to ICH/EU/GCP and national local laws. - Age 18-65 years. - A diagnosis of untreated Ph- ALL or LL is required, either de novo or secondary to chemo-radiotherapy for other cancer. Pretreatment with low-dose corticosteroids in patients presenting with hyperleukocytosis is allowed. All diagnostic procedures need to be performed on freshly obtained bone marrow (BM) and peripheral blood (PB) samples. The diagnosis must be one of: de novo ALL, secondary ALL, B-/T-cell LL Full cytological, cytochemical, cytogenetic and immunobiological disease characterization according to EGIL and WHO classifications. Bone marrow and peripheral blood sampling (ALL) or biopsy specimen (LL) are required for MRD study. Detailed indications on patient registration, storage of representative diagnostic material and diagnostic work-up, including the forwarding of samples for MRD study are given in Appendix B. - Bone marrow and peripheral blood sampling (ALL) or biopsy specimen (LL) for MRD study. - ECOG performance status 0-2, unless a performance of 3 is unequivocally caused by the disease itself and not by preexisting comorbidity, and is considered and/or documented to be reversible following the application of antileukemic therapy and appropriate supportive measures. Exclusion Criteria: - Diagnosis of Burkitt's leukemia or lymphoma. - Down's syndrome - Pre-existing, uncontrolled pathology such as heart failure (congestive/ischemic, acute myocardial infarction within the past 3 months, untreatable arrhythmias, NYHA classes III and IV), severe liver disease with serum bilirubin >3 mg/dL and/or ALT >3 x upper normal limit (unless attributable to ALL), kidney function impairment with serum creatinine >2 mg/dL (unless attributable to ALL), and severe neuropsychiatric disorder that impairs the patient's ability to understand and sign the informed consent, or to cope with the intended treatment plan. N.B. For altered liver and kidney function tests, eligibility criteria can be reassessed at 24-96 hours, following the institution of adequate supportive measures. - Pre-existing HIV positive serology (i.e. already known before enrolment). If HIV positivity is detected after enrolment, the patient is sent off study. - A history of cancer that is not in a remission phase following surgery and/or radiotherapy and/or chemotherapy, with life expectancy <1 year. - Pregnancy declared by the patient herself, unless a decision is taken with the patient to induce a therapeutic abortion in order to carry on with ALL therapy. A pregnancy test is performed at diagnosis but does not preclude the enrolment into study. Fertile patients will be advised to adopt contraceptive methods while on treatment. |
Country | Name | City | State |
---|---|---|---|
Italy | S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo | Alessandria | |
Italy | Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI | Ancona | |
Italy | U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno | Ascoli Piceno | |
Italy | Az.Ospedaliera S.G.Moscati | Avellino | |
Italy | UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro | Bari | |
Italy | Azienda Ospedaliera - Papa Giovanni XXIII | Bergamo | |
Italy | Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi | Bologna | |
Italy | Comprensorio Sanitario di Bolzano - Azienda Sanitaria dell'Alto Adige - Ematologia e Centro TMO - Ospedale S.Maurizio | Bolzano | |
Italy | Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia | Brescia | |
Italy | Divisione di Ematologia Ospedale A. Perrino | Brindisi | |
Italy | Ao Brotzu, Presidio Ospedaliero A. Businco - Cagliari - Sc Ematologia E Ctmo | Cagliari | |
Italy | CTMO - Ematologia - Ospedale "Binaghi" | Cagliari | |
Italy | Unità Operativa Complessa di Onco-Ematologia - A.O. S.Anna e S.Sebastiano | Caserta | |
Italy | Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto" | Catania | |
Italy | Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova | Cona | |
Italy | Sezione di Ematologia C.T.M.O. Istituti Ospitalieri | Cremona | |
Italy | S.C. Ematologia ASO S. Croce e Carle | Cuneo | |
Italy | IRCCS_AOU San Martino-IST.Clinica Ematologica | Genova | |
Italy | ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE | Lecce | |
Italy | Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte" P.O. Papardo | Messina | |
Italy | U.O. di Ematologia- Ospedale dell'Angelo - Mestre | Mestre | |
Italy | Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora | Milano | |
Italy | Ospedale Niguarda " Ca Granda" - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano | Milano | |
Italy | U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele | Milano | |
Italy | UO Ematologia - AOU Policlinico di Modena | Modena | |
Italy | Azienda Ospedaliera "S.Gerardo" | Monza | |
Italy | Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli" | Napoli | |
Italy | S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro | Novara | |
Italy | U.O. CTMO Ematologia - Osp. S.Francesco | Nuoro | |
Italy | Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 | Orbassano | |
Italy | Università degli Studi di Padova - Ematologia ed Immunologia Clinica | Padova | |
Italy | Ospedali Riuniti "Villa Sofia-Cervello" | Palermo | |
Italy | U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico "Paolo Giaccone" | Palermo | |
Italy | Casa Di Cura La Maddalena S.P.A. - Dipartimento Oncologico Di Iii Livello - Palermo - Uo Oncoematologia E Tmo | Palmero | |
Italy | Day Hospital dell'U.O.C di Ematologia e CTMO Padiglione 1 TORRE DELLE MEDICINE, 6° piano | Parma | |
Italy | S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo | Pavia | |
Italy | Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia | Perugia | |
Italy | Div. di Ematologia di Muraglia - CTMO Ospedale San Salvatore | Pesaro | |
Italy | U.O. Ematologia Clinica - Azienda USL di Pescara | Pescara | |
Italy | Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto | Piacenza | |
Italy | Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia | Pisa | |
Italy | Ematologia - Ospedale San Carlo | Potenza | |
Italy | Dipartimento Oncologico - Ospedale S.Maria delle Croci | Ravenna | |
Italy | Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli" | Reggio Calabria | |
Italy | Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova | Reggio Emilia | |
Italy | Ospedale "Infermi" | Rimini | |
Italy | Az. Ospedaliera "Sant' Andrea"-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia | Roma | |
Italy | Complesso Ospedaliero S. Giovanni Addolorata | Roma | |
Italy | S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena | Roma | |
Italy | U.O.C. Ematologia - Ospedale S.Eugenio | Roma | |
Italy | Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia | Roma | |
Italy | Sezione di Ematologia Cancer Center Humanitas | Rozzano | |
Italy | UOC di Ematologia e Trapianti di Cellule Staminali Emopoietiche - AOU San Giovanni di Dio e Ruggi D'Aragona | Salerno | |
Italy | Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza | San Giovanni Rotondo | |
Italy | U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte" | Siena | |
Italy | Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista | Torino | |
Italy | Divisione di Ematologia dell' Università degli Studi di Torino - "Città della Salute e della Scienza di Torino" | Torino | |
Italy | Ospedale Mauriziano Umberto I - Torino - Scdu Ematologia | Torino | |
Italy | U.L.S.S. 9 UOC Ematologia - Ospedale Ca' Foncello | Treviso | |
Italy | Clinica Ematologica-Centro Trapianti e Terapie cellulari Azienda Ospedaliero-Universitaria, Udine | Udine | |
Italy | Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi | Verona |
Lead Sponsor | Collaborator |
---|---|
Gruppo Italiano Malattie EMatologiche dell'Adulto |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients on disease free survival (DFS). | DFS is defined as the time interval between the evaluation of CR and relapse of the disease or death in first Complete Response (CR); patients still alive, in first CR, will be censored at the time of the last follow-up. In this case, the DFS will be truncated at 2 years. | At two years. | |
Secondary | The rate of patients in complete remission (CR). | After approximately two months from start of treatment. | ||
Secondary | The rate of early bone marrow MRD negativity. | At 4 timepoints (week 4, 10, 16 22). | ||
Secondary | Early bone marrow MRD response (<10-4). | At 4 weeks following induction cycle 1 with Peg-ASP. | ||
Secondary | Overall Survival (OS) estimation. | At two years from diagnosis. | ||
Secondary | Cumulative Incidence of Relapse (CIR) estimation. | At two years from CR achievement. | ||
Secondary | The rate of patients dead due Treatment-related mortality (TRM). | By the end of the study (4.5 years from first centre opened). | ||
Secondary | Composite DFS, OS, CIR. | At two years from CR achievement and rate of TRM in LL patients. | ||
Secondary | Description of Minimal Residual Disease (MRD) monitoring. | During treatment at time point 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12. | ||
Secondary | Number of Severe Infections (SI) during treatment. | Description: Number and type. | At the end of the study (4.5 years from first centre opened). | |
Secondary | Rate of Adverse Events (AE). | Excluding SI. | By the end of the study (4.5 years from first centre opened) | |
Secondary | Composite evaluation of impact of age (=55 and >55) and risk category group (SR, HR, VHR - as defined) on outcomes: DFS, CIR. | At two years for CR achievement, OS at two years from diagnosis and TRM. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00506207 -
A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy
|
Phase 1 | |
Terminated |
NCT00506168 -
Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer
|
Phase 2 | |
Withdrawn |
NCT03226236 -
Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC
|
Phase 2 | |
Completed |
NCT02716766 -
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Terminated |
NCT02919462 -
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
|
Phase 2 | |
Recruiting |
NCT00506571 -
Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT01420146 -
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
|
Phase 1 | |
Recruiting |
NCT00507143 -
Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan
|
N/A |